Kami menyediakan berita terkini dari dunia ekonomi dan kewangan
(RTTNews) - Corcept Therapeutics Inc. (CORT) Tuesday announced that the New Jersey district court has issued a decision that Teva Pharmaceuticals Ltd. (TEVA) does not infringe any asserted claims of Corcept's U.S. Patents 10,195,214 and 10,842,800.
In the pre-market, shares are at $21.39, down 34.14 percent from the previous close of $32.88 on a volume of 949,026.
Corcept is planning to pursue its appeal vigorously.
Corcept's CEO Joseph Belanoff said, "This disappointing decision is based on legal and factual errors we are confident will be reversed on appeal...Failure to recognize the novelty and import of discoveries like these would fundamentally change the law, to the detriment of the many patients whom innovative companies seek to serve."
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
© 2024 Lime Trading (CY) Ltd
Lime Trading (CY) Ltd diberi kuasa dan dikawal selia oleh Suruhanjaya Sekuriti dan Bursa Cyprus mengikut lesen No.281/15 yang dikeluarkan pada 25/09/2015. Tanda dagangan "Just2Trade" dimiliki oleh LimeTrading (CY) Ltd.
Nombor Pendaftaran: HE 341520
Address: Lime Trading (CY) Ltd
Magnum Business Center, Office 4B, Spyrou Kyprianou Avenue 78
Limassol 3076, Cyprus
Penafian:
Semua promosi, bahan dan maklumat laman web ini mungkin telah dikenakan syarat.
Sila hubungi syarikat untuk maklumat lanjut.
Dagangan di pasaran kewangan membawa risiko.Nilai pelaburan boleh meningkat dan menurun dan pelabur mungkin kehilangan semua modal pelaburan mereka.Dalam kes produk yang dimanfaatkan, kerugian mungkin lebih daripada modal awal yang dilaburkan. Maklumat terperinci mengenai risiko yang berkaitan dengan perdagangan di pasaran kewangan boleh didapati dalam pendedahan risiko penuh..